Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) will present at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 4:30 PM ET. The management team will participate and deliver prepared remarks.

A live webcast will be available on the company website under Investors and a replay will be posted about one hour after the event and archived for approximately one month.

News Market Reaction – NBIX

-0.25%

-0.25% Session close to close

In the Mar 11 session, NBIX declined 0.25%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details NBIX management’s upcoming appearance at the Stifel 2026 Virtual CNS Forum...

Analysis

This announcement details NBIX management’s upcoming appearance at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 4:30 PM EST, with a webcast and replay available on the investor website. It follows a series of recent updates spanning earnings, new clinical trial starts, and comparative INGREZZA data. Investors tracking the story may focus more on how conference commentary connects to prior earnings guidance, late‑stage pipeline progress, and recent clinical initiatives than on the event logistics themselves.

Key Figures

Presentation time: 4:30 PM EST Event date: March 17, 2026 Webcast replay timing: ~1 hour after event

3 metrics

Presentation time 4:30 PM EST Stifel 2026 Virtual CNS Forum on March 17, 2026

Event date March 17, 2026 Management presentation at Stifel 2026 Virtual CNS Forum

Webcast replay timing ~1 hour after event Replay available on company website after forum presentation

Historical Context

5 past events · Latest: Feb 24 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 24	Conference participation	Neutral	+0.1%	Announcement of March 2026 investor conference presentations and webcast access.
Feb 11	Earnings results	Positive	-10.4%	Strong Q4 and 2025 sales, income, and 2026 guidance with solid cash balance.
Jan 26	Clinical trial start	Positive	-1.2%	Initiation of Phase 2 study of NBI-1065890 in adults with tardive dyskinesia.
Jan 21	Earnings call setup	Neutral	+1.4%	Scheduling and access details for Q4 and year-end 2025 earnings call and webcast.
Jan 15	Clinical data update	Positive	-1.5%	Head-to-head INGREZZA VMAT2 occupancy data versus AUSTEDO XR at therapeutic doses.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent NBIX news often relates to conferences and clinical or data updates; fundamentally positive items have sometimes seen negative next-day price moves.

Recent Company History

Over the last few months, NBIX has reported several notable developments. An earnings release on Feb 11, 2026 highlighted strong 2025 sales and cash, yet the stock fell 10.43%. A Phase 2 trial initiation for NBI‑1065890 on Jan 26, 2026 and head‑to‑head INGREZZA VMAT2 occupancy data on Jan 15, 2026 were followed by modest declines. Routine conference and webcast announcements in late January and February saw only small, mixed reactions, similar in nature to today’s Stifel forum update.

Key Terms

cns, biopharmaceutical, tardive dyskinesia, huntington's disease, +4 more

8 terms

cns medical

"Stifel 2026 Virtual CNS Forum at 4:30 PM EST on March 17, 2026."

CNS stands for the central nervous system, the brain and spinal cord that control thought, movement and bodily functions. For investors, CNS-focused products and research matter because therapies aimed at this “delicate wiring” are scientifically challenging, often carry higher development and regulatory risk, and can take longer to prove safe and effective — but successful treatments also tend to command large markets and premium pricing.

biopharmaceutical medical

"Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose:"

A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.

tardive dyskinesia medical

"FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic"

A chronic movement disorder marked by repetitive, involuntary motions—often of the face, tongue, or limbs—that can develop after long-term use of certain psychiatric or neurological medications. It matters to investors because the condition creates medical need, regulatory scrutiny, potential for expensive treatments or liability, and can shape the commercial value of drugs in development or on the market; think of it as a persistent side effect that can change a drug’s price tag and sales prospects.

huntington's disease medical

"treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital"

A hereditary brain disorder caused by a faulty gene that progressively damages nerve cells, leading to uncontrollable movements, thinking and mood problems, and a shortened lifespan. It matters to investors because the disease creates a clear medical need and potential market for treatments, so news about clinical trial results, regulatory progress, or drug approvals can strongly move biotech and pharmaceutical stock values. Think of it as a predictable, inherited mechanical flaw in a complex machine that companies are trying to fix.

congenital adrenal hyperplasia medical

"chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis*"

Congenital adrenal hyperplasia is a group of inherited disorders in which the adrenal glands lack an enzyme needed to make certain hormones, causing a chronic imbalance of cortisol, aldosterone and/or sex hormones. Think of it as a factory assembly line missing a key part, so the body overproduces some products and underproduces others, requiring lifelong monitoring or hormone treatment. For investors, it matters because diagnosis, ongoing therapy, newborn screening and potential new drugs or gene therapies can drive medical spending, regulatory approvals and market opportunity in endocrinology and rare disease care.

endometriosis medical

"hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline"

Endometriosis is a chronic condition where tissue similar to the lining of the uterus grows outside the uterus, often causing pain and fertility problems. It can impact a person's health and quality of life, potentially leading to increased healthcare costs and affecting workforce productivity. For investors, understanding conditions like endometriosis highlights the importance of healthcare innovations and markets related to women's health.

uterine fibroids medical

"endometriosis* and uterine fibroids*, as well as a robust pipeline including"

Uterine fibroids are noncancerous growths that develop in the muscular wall of the uterus, often described like small rubbery lumps within the organ. They matter to investors because they affect a large number of people of reproductive age and drive demand for diagnostics, medications, minimally invasive procedures and surgical devices, creating revenue opportunities and regulatory, reimbursement and competitive considerations for healthcare companies.

fda-approved regulatory

"The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, March 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the Stifel 2026 Virtual CNS Forum at 4:30 PM EST on March 17, 2026.

The live webcast can be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-stifel-2026-virtual-cns-forum-302709863.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences (NBIX) present at the Stifel 2026 Virtual CNS Forum?

Neurocrine Biosciences will present on March 17, 2026 at 4:30 PM ET. According to the company, members of the management team will participate and the session will be webcast live on the company's investor website for real-time viewing.

How can investors watch the NBIX presentation from the Stifel 2026 Virtual CNS Forum?

Investors can watch a live webcast via the company's investor website at neurocrine.com. According to the company, the webcast link is under Investors and a replay will be posted about one hour after the event concludes.

Will Neurocrine Biosciences (NBIX) provide a replay of the Stifel 2026 Virtual CNS Forum presentation?

Yes, a replay will be available approximately one hour after the presentation concludes and will be archived for about one month. According to the company, the replay can be accessed on the investor section of neurocrine.com.

What topics will Neurocrine Biosciences (NBIX) management cover at the Stifel 2026 Virtual CNS Forum?

The announcement confirms management will participate but does not list specific topics. According to the company, the presentation will feature the management team; viewers should consult the webcast for the full agenda and remarks.

Where can I find the webcast and archived replay for the NBIX Stifel 2026 presentation?

The live webcast and archived replay are available on Neurocrine Biosciences' investor website at neurocrine.com. According to the company, the replay will appear about one hour after the live event and remain archived for roughly one month.